New @TheLancetRheum Series on Giant cell arteritis explores the possibilities of a more tailored approach to treatment with regard to clinical phenotypes, imaging parameters, and inflammatory pathways https://t.co/sKTEcl3E6T #LancetRheumatology
[Article] A Diagnostic Algorithm Based on a Simple Clinical Prediction Rule for the Diagnosis of Cranial Giant Cell Arteritis | J Clin Med 2021 https://t.co/UR4mfsxca0
« Our results suggest a majority but not a complete consensus for route and dose of corticosteroid treatment in GCA and confirm conventional recommendations for high dose IV corticosteroids for GCA with visual loss »
[Free Article] Vision loss in patients with giant cell arteritis treated with tocilizumab - Arthritis Care Res 2021
#giantcellarteritis#GCA#Horton#tocilizumab https://t.co/ev4721bM31
NEW RESEARCH: The open-label extension phase of the #GiACTA trial; 42% of patients with #GiantCellArteritis who achieve remission with #tocilizumab treatment maintain drug-free remission for 2 years after stopping treatment https://t.co/ehsoKA2eOL #LancetRheumatology
Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study - J Transl Autoimmun 2020 #GCA#giantcellarteritis#Horton https://t.co/MpxlUeqTzt
NEW VIEWPOINT—"Clinical pathways for patients with giant cell arteritis during the #COVID19 pandemic"
@Sarah_L_Mackie and colleagues reflect on rapid service adaptations, evaluate challenges, and consider implications for the future https://t.co/NQPBybF0QJ @philipcrobinson#GCA
Restauration de la réponse T régulatrice après traitement par tocilizumab au cours de l’artérite à cellules géantes.
par M.Samson #SNFMIDijon2020#GCA#Vasculitis
Treg sous Corticoïdes ou CTC + Toci
Passionnant !